Heterogeneity in reporting venous thromboembolic phenotypes in COVID-19: methodological issues and clinical implications.
Anastasios KolliasKοnstantinos G KyriakoulisGeorge S StergiouKonstantinos SyrigosPublished in: British journal of haematology (2020)
COVID-19 is associated with increased risk of venous thromboembolic events (VTE). However, there is significant heterogeneity in the thromboembolic phenotypes of COVID-19 patients (deep vein thrombosis, pulmonary embolism/thrombosis). The latter might be partly attributed to the variation in VTE risk factors in COVID-19 patients including: (i) patients' characteristics; (ii) hospitalization conditions and interventions; and (iii) SARS-CoV-2-specific factors (coagulopathy, endothelial injury/microthrombosis). Furthermore, there is methodological heterogeneity in relation to the assessment of VTE (indications for screening, diagnostic methodology, etc). Physicians should be aware of the increased VTE risk, strongly consider VTE screening, and use thromboprophylaxis in all hospitalized patients.
Keyphrases
- venous thromboembolism
- sars cov
- pulmonary embolism
- direct oral anticoagulants
- respiratory syndrome coronavirus
- single cell
- risk factors
- end stage renal disease
- inferior vena cava
- coronavirus disease
- ejection fraction
- atrial fibrillation
- newly diagnosed
- primary care
- chronic kidney disease
- peritoneal dialysis
- physical activity
- prognostic factors
- emergency department
- endothelial cells